JP2005320354A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005320354A5 JP2005320354A5 JP2005226695A JP2005226695A JP2005320354A5 JP 2005320354 A5 JP2005320354 A5 JP 2005320354A5 JP 2005226695 A JP2005226695 A JP 2005226695A JP 2005226695 A JP2005226695 A JP 2005226695A JP 2005320354 A5 JP2005320354 A5 JP 2005320354A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- administration composition
- composition according
- cellulose
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 52
- 229940079593 drug Drugs 0.000 claims 34
- 239000003814 drug Substances 0.000 claims 34
- 229920000642 polymer Polymers 0.000 claims 28
- 229920002678 cellulose Polymers 0.000 claims 18
- 235000010980 cellulose Nutrition 0.000 claims 17
- 239000001913 cellulose Substances 0.000 claims 13
- 239000006185 dispersion Substances 0.000 claims 13
- -1 hydroxypropylmethylcellulose acetates Chemical class 0.000 claims 12
- 239000011159 matrix material Substances 0.000 claims 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 7
- 229920001577 copolymer Polymers 0.000 claims 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 7
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 claims 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 6
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims 5
- 229920002301 cellulose acetate Polymers 0.000 claims 5
- 229920000609 methyl cellulose Polymers 0.000 claims 5
- 239000001923 methylcellulose Substances 0.000 claims 5
- 235000010981 methylcellulose Nutrition 0.000 claims 5
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 5
- 125000005591 trimellitate group Chemical group 0.000 claims 5
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 4
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 claims 4
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 4
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 3
- 238000013270 controlled release Methods 0.000 claims 3
- 125000005456 glyceride group Chemical class 0.000 claims 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 3
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 3
- 239000007962 solid dispersion Substances 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 2
- ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims 2
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims 2
- 230000000561 anti-psychotic effect Effects 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 229940127219 anticoagulant drug Drugs 0.000 claims 2
- 239000002249 anxiolytic agent Substances 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 150000002334 glycols Chemical class 0.000 claims 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000005498 phthalate group Chemical class 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 1
- DTCCVIYSGXONHU-CJHDCQNGSA-N (z)-2-(2-phenylethenyl)but-2-enedioic acid Chemical compound OC(=O)\C=C(C(O)=O)\C=CC1=CC=CC=C1 DTCCVIYSGXONHU-CJHDCQNGSA-N 0.000 claims 1
- FUQOTYRCMBZFOL-UHFFFAOYSA-N 5-chloro-1H-indole-2-carboxylic acid Chemical compound ClC1=CC=C2NC(C(=O)O)=CC2=C1 FUQOTYRCMBZFOL-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 229920000856 Amylose Polymers 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Chemical class 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- 229920001800 Shellac Polymers 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims 1
- ZNPLZHBZUSCANM-UHFFFAOYSA-N acetic acid;benzene-1,3-dicarboxylic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC(C(O)=O)=C1 ZNPLZHBZUSCANM-UHFFFAOYSA-N 0.000 claims 1
- FMTQGBMMIVVKSN-UHFFFAOYSA-N acetic acid;terephthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=C(C(O)=O)C=C1 FMTQGBMMIVVKSN-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims 1
- 229920006243 acrylic copolymer Polymers 0.000 claims 1
- 239000003470 adrenal cortex hormone Substances 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000001195 anabolic effect Effects 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 230000000954 anitussive effect Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000049 anti-anxiety effect Effects 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 229940035678 anti-parkinson drug Drugs 0.000 claims 1
- 230000000842 anti-protozoal effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940127088 antihypertensive drug Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000003904 antiprotozoal agent Substances 0.000 claims 1
- 229940124584 antitussives Drugs 0.000 claims 1
- 239000003699 antiulcer agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 229940125717 barbiturate Drugs 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- VHEMBTYWURNBQQ-UHFFFAOYSA-N butanoic acid;phthalic acid Chemical compound CCCC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O VHEMBTYWURNBQQ-UHFFFAOYSA-N 0.000 claims 1
- 239000007894 caplet Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims 1
- 230000003177 cardiotonic effect Effects 0.000 claims 1
- 229920001727 cellulose butyrate Polymers 0.000 claims 1
- 229920003086 cellulose ether Polymers 0.000 claims 1
- 229920006218 cellulose propionate Polymers 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000002475 cognitive enhancer Substances 0.000 claims 1
- 239000003218 coronary vasodilator agent Substances 0.000 claims 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 claims 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 claims 1
- 229940097362 cyclodextrins Drugs 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 230000003291 dopaminomimetic effect Effects 0.000 claims 1
- 229960001389 doxazosin Drugs 0.000 claims 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 claims 1
- 239000002895 emetic Substances 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims 1
- 229960001381 glipizide Drugs 0.000 claims 1
- 239000003326 hypnotic agent Substances 0.000 claims 1
- 230000000147 hypnotic effect Effects 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- QQVIHTHCMHWDBS-UHFFFAOYSA-L isophthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC(C([O-])=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-L 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims 1
- 229960001597 nifedipine Drugs 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- KQOCPYKMLMTOOP-UHFFFAOYSA-N phthalic acid;propanoic acid Chemical compound CCC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O KQOCPYKMLMTOOP-UHFFFAOYSA-N 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 229920001223 polyethylene glycol Chemical class 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229920002689 polyvinyl acetate Polymers 0.000 claims 1
- 239000011118 polyvinyl acetate Substances 0.000 claims 1
- 229960001289 prazosin Drugs 0.000 claims 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 229940125723 sedative agent Drugs 0.000 claims 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 1
- 229960002073 sertraline Drugs 0.000 claims 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims 1
- 239000004208 shellac Substances 0.000 claims 1
- 229940113147 shellac Drugs 0.000 claims 1
- 235000013874 shellac Nutrition 0.000 claims 1
- 229960003310 sildenafil Drugs 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 239000008137 solubility enhancer Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 150000005846 sugar alcohols Polymers 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 claims 1
- 229960002906 trimazosin Drugs 0.000 claims 1
- YNZXWQJZEDLQEG-UHFFFAOYSA-N trimazosin Chemical compound N1=C2C(OC)=C(OC)C(OC)=CC2=C(N)N=C1N1CCN(C(=O)OCC(C)(C)O)CC1 YNZXWQJZEDLQEG-UHFFFAOYSA-N 0.000 claims 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 1
- 229960004688 venlafaxine Drugs 0.000 claims 1
- 229920003169 water-soluble polymer Polymers 0.000 claims 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims 1
- 229960000607 ziprasidone Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11940099P | 1999-02-10 | 1999-02-10 | |
| US60/119400 | 1999-02-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000033446A Division JP4355779B2 (ja) | 1999-02-10 | 2000-02-10 | マトリックス制御放出デバイス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005320354A JP2005320354A (ja) | 2005-11-17 |
| JP2005320354A5 true JP2005320354A5 (https=) | 2006-06-01 |
| JP4694298B2 JP4694298B2 (ja) | 2011-06-08 |
Family
ID=22384221
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000033446A Expired - Fee Related JP4355779B2 (ja) | 1999-02-10 | 2000-02-10 | マトリックス制御放出デバイス |
| JP2005226695A Expired - Lifetime JP4694298B2 (ja) | 1999-02-10 | 2005-08-04 | マトリックス制御放出デバイス |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000033446A Expired - Fee Related JP4355779B2 (ja) | 1999-02-10 | 2000-02-10 | マトリックス制御放出デバイス |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1027887B1 (https=) |
| JP (2) | JP4355779B2 (https=) |
| AT (1) | ATE404178T1 (https=) |
| BR (1) | BR0000359A (https=) |
| CA (1) | CA2298245C (https=) |
| DE (1) | DE60039802D1 (https=) |
| ES (1) | ES2310164T3 (https=) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000281561A (ja) * | 1999-03-26 | 2000-10-10 | Ajinomoto Co Inc | 新規溶媒法固体分散体製剤 |
| CN1402629A (zh) * | 1999-12-23 | 2003-03-12 | 辉瑞产品公司 | 提供提高的药物浓度的药物组合物 |
| US20010053791A1 (en) * | 2000-03-16 | 2001-12-20 | Babcock Walter C. | Glycogen phosphorylase inhibitor |
| DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| KR20020014570A (ko) * | 2000-08-18 | 2002-02-25 | 김충섭 | 고체분산화시킨 무정형 이프리플라본의 제조방법 |
| GB0027357D0 (en) * | 2000-11-09 | 2000-12-27 | Bradford Particle Design Plc | Particle formation methods and their products |
| EP1269994A3 (en) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
| OA12625A (en) * | 2001-06-22 | 2006-06-12 | Pfizer Prod Inc | Pharmaceutical compositions of adsorbates of amorphous drug. |
| JP2004534812A (ja) | 2001-06-22 | 2004-11-18 | ファイザー・プロダクツ・インク | 薬物および中性ポリマーの分散物の医薬組成物 |
| CA2450748A1 (en) * | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions containing polymer and drug assemblies |
| TNSN03137A1 (en) | 2001-06-22 | 2005-12-23 | Pfizer Prod Inc | PHARMACEUTICAL COMPOSITIONS COMPRISING LOW SOLUBILITY AND / OR ACID SENSITIVE DRUGS AND NEUTRALIZED ACID POLYMERS. |
| BR0210520A (pt) | 2001-06-22 | 2004-06-22 | Pfizer Prod Inc | Composições farmacêuticas de dispersões de fármacos amorfos misturados com polìmeros |
| US7105178B2 (en) | 2001-07-17 | 2006-09-12 | Sun Pharmaceutical Industries Limited | Cardiotonic composition |
| EP1439824A2 (en) * | 2001-10-29 | 2004-07-28 | Therics, Inc. | Three-dimensional suspension printing of dosage forms |
| EP1474123A1 (en) * | 2002-01-03 | 2004-11-10 | LEK Pharmaceuticals D.D. | Controlled release pharmaceutical formulation containing venlafaxine |
| DE60320940D1 (de) | 2002-02-01 | 2008-06-26 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien |
| WO2003063831A2 (en) | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Immediate release dosage forms containing solid drug dispersions |
| BR0307515A (pt) | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão |
| PL372247A1 (en) | 2002-02-01 | 2005-07-11 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| CN1625397A (zh) * | 2002-02-01 | 2005-06-08 | 辉瑞产品公司 | 胆固醇酯转移蛋白抑制剂的控制释放药物剂型 |
| US6864373B2 (en) * | 2002-05-13 | 2005-03-08 | Pharmacia Corporation | Stable amorphous celecoxib composite and process therefor |
| SI21223A (sl) * | 2002-06-19 | 2003-12-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Farmacevtska formulacija s stabiliziranim amorfnim donepezilijevim kloridom |
| EP1530457B1 (en) | 2002-08-12 | 2009-09-09 | Bend Research, Inc. | Pharmaceutical compositions of drugs in semi-ordered form and polymers |
| US7423004B2 (en) | 2003-01-31 | 2008-09-09 | Smithkline Beecham Corporation | Solid dispersion compositions |
| IL154370A0 (en) * | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
| DE10325989A1 (de) * | 2003-06-07 | 2005-01-05 | Glatt Gmbh | Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung |
| BRPI0413277A (pt) | 2003-08-04 | 2006-10-10 | Pfizer Prod Inc | composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas |
| CL2004001884A1 (es) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
| BRPI0413363A (pt) * | 2003-08-04 | 2006-10-10 | Pfizer Prod Inc | formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| PE20142101A1 (es) * | 2004-03-17 | 2014-12-27 | Novartis Ag | Composiciones farmaceuticas de aliskiren |
| US20090142404A1 (en) * | 2004-08-31 | 2009-06-04 | Pfizer Inc | Pharmaceutical dosage forms comprising a low-solubility drug and a polymer |
| EP1789022A2 (en) * | 2004-08-31 | 2007-05-30 | Pfizer Products Incorporated | Controlled release dosage forms combining immediate release and sustained release of low-solubility drug |
| WO2006035433A2 (en) | 2004-09-29 | 2006-04-06 | Chemagis Ltd. | Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride |
| MX2007007836A (es) | 2004-12-27 | 2007-08-20 | Eisai R&D Man Co Ltd | Metodo para estabilizar un farmaco anti-demencia. |
| US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
| CA2594694A1 (en) | 2005-01-28 | 2006-08-03 | Pfizer Products Inc. | Drying of drug-containing particles |
| WO2006082500A1 (en) * | 2005-02-03 | 2006-08-10 | Pfizer Products Inc. | Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| CN101272767B (zh) * | 2005-08-29 | 2012-08-29 | 赛诺菲-安万特美国有限责任公司 | 7-氯-N,N,5-三甲基-4-氧-3-苯基-3,5-二氢-4H-哒嗪并[4,5-b]吲哚-1-乙酰胺的无定形固体分散体 |
| WO2008012617A1 (en) | 2006-07-21 | 2008-01-31 | Pfizer Products Inc. | Drying of drug-containing particles |
| PE20081506A1 (es) | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | Formulaciones de ansamicina |
| BRPI0807939A2 (pt) * | 2007-04-03 | 2014-07-01 | Reddys Lab Ltd Dr | Formas sólidas de pemetrexed |
| JP2010526848A (ja) * | 2007-05-11 | 2010-08-05 | エフ．ホフマン−ラ ロシュ アーゲー | 難溶性薬物用の医薬組成物 |
| JP5048398B2 (ja) * | 2007-06-13 | 2012-10-17 | 大蔵製薬株式会社 | 抗真菌剤の医薬組成物 |
| SMT202000093T1 (it) * | 2009-06-16 | 2020-03-13 | Pfizer | Forme di dosaggio di apixaban |
| US8329208B2 (en) * | 2009-07-28 | 2012-12-11 | Methylation Sciences International Srl | Pharmacokinetics of S-adenosylmethionine formulations |
| ES2414384T3 (es) * | 2011-05-11 | 2013-07-19 | Ratiopharm Gmbh | Composición de liberación modificada que comprende ranolazina |
| JO3339B1 (ar) * | 2012-09-11 | 2019-03-13 | Shanghai Inst Pharmaceutical Ind | شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه |
| JP5877935B2 (ja) | 2012-10-17 | 2016-03-08 | メチレーション・サイエンシーズ・インターナショナル・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティＭｅｔｈｙｌａｔｉｏｎ Ｓｃｉｅｎｃｅｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｓｒｌ | Ｓ−アデノシルメチオニンおよび没食子酸エステルを含む組成物 |
| JP5836980B2 (ja) | 2013-01-11 | 2015-12-24 | 信越化学工業株式会社 | 薬物含有粒子、固形製剤及び薬物含有粒子の製造方法 |
| EP3076951B1 (en) * | 2013-12-05 | 2020-09-30 | Celal Albayrak | Process for the production of drug formulations for oral administration |
| AU2015257658A1 (en) * | 2014-05-08 | 2016-11-10 | Oncoethix Gmbh | Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds |
| ES3063790T3 (en) | 2015-06-09 | 2026-04-20 | Lonza Sales Ag | Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules |
| GB201609222D0 (en) | 2016-05-25 | 2016-07-06 | F2G Ltd | Pharmaceutical formulation |
| US11819503B2 (en) | 2019-04-23 | 2023-11-21 | F2G Ltd | Method of treating coccidioides infection |
| CN113840595A (zh) * | 2019-05-17 | 2021-12-24 | 葛兰素史密斯克莱知识产权发展有限公司 | 基质组合物，其包含(S)-5-苄基-N-(5-甲基-4-氧代-2,3,4,5-四氢苯并[b][1,4]氧氮杂环庚三烯-3-基)-4H-1,2,4-三唑-3-甲酰胺 |
| JP7812785B2 (ja) * | 2019-09-18 | 2026-02-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｙｋ２阻害薬の剤形 |
| WO2024238657A2 (en) | 2023-05-15 | 2024-11-21 | Bonafide Health, Llc | Sleep-improving compositions and methods of use |
| AU2024344754A1 (en) | 2023-09-21 | 2026-04-02 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors for use in the treatment of inflammatory bowel disease |
| WO2026033474A1 (en) | 2024-08-08 | 2026-02-12 | Takeda Pharmaceutical Company Limited | Deuterated compounds and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5649314A (en) * | 1979-07-05 | 1981-05-02 | Yamanouchi Pharmaceut Co Ltd | Lasting pharmaceutical composition having prolonged action and its preparation |
| JPS5948810B2 (ja) * | 1980-03-22 | 1984-11-29 | 山之内製薬株式会社 | ニカルジピン持続性製剤用組成物 |
| JPS58116414A (ja) * | 1981-12-23 | 1983-07-11 | Yamanouchi Pharmaceut Co Ltd | ニカルジピン持続性製剤用球形顆粒およびその製造法 |
| JP2528706B2 (ja) * | 1988-05-30 | 1996-08-28 | ゼリア新薬工業株式会社 | ジヒドロピリジン化合物の製剤組成物 |
| TW212139B (https=) * | 1991-04-15 | 1993-09-01 | Yamanouchi Pharma Co Ltd | |
| IT1250654B (it) * | 1991-07-08 | 1995-04-21 | Farcon Ag | Metodo per la preparazione di forme farmaceutiche orali a rilascio prolungato contenenti sostanze attive a solubilita' dipendente dal valore di ph. |
| JP2516524B2 (ja) * | 1992-04-27 | 1996-07-24 | 大洋薬品工業株式会社 | 持続性製剤 |
| US5773025A (en) * | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
| HUT77530A (hu) * | 1994-05-06 | 1998-05-28 | Pfizer Inc. | Azitromicint tartalmazó, szabályozott hatóanyag-felszabadítású dózisformák |
| DE19515972A1 (de) * | 1995-05-02 | 1996-11-07 | Bayer Ag | Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung |
| IE80467B1 (en) * | 1995-07-03 | 1998-07-29 | Elan Corp Plc | Controlled release formulations for poorly soluble drugs |
| TW487582B (en) * | 1995-08-11 | 2002-05-21 | Nissan Chemical Ind Ltd | Method for converting sparingly water-soluble medical substance to amorphous state |
| ES2287971T3 (es) * | 1997-08-11 | 2007-12-16 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas con biodisponibilidad incrementada. |
-
2000
- 2000-01-26 AT AT00300546T patent/ATE404178T1/de not_active IP Right Cessation
- 2000-01-26 DE DE60039802T patent/DE60039802D1/de not_active Expired - Lifetime
- 2000-01-26 EP EP00300546A patent/EP1027887B1/en not_active Expired - Lifetime
- 2000-01-26 ES ES00300546T patent/ES2310164T3/es not_active Expired - Lifetime
- 2000-02-09 CA CA002298245A patent/CA2298245C/en not_active Expired - Lifetime
- 2000-02-10 BR BR0000359-0A patent/BR0000359A/pt not_active Application Discontinuation
- 2000-02-10 JP JP2000033446A patent/JP4355779B2/ja not_active Expired - Fee Related
-
2005
- 2005-08-04 JP JP2005226695A patent/JP4694298B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005320354A5 (https=) | ||
| JP6084161B2 (ja) | ７−［４−（４−ベンゾ［ｂ］チオフェン−４−イル−ピペラジン−１−イル）ブトキシ］−１Ｈ−キノリン−２−オン又はその塩を含む錠剤 | |
| TWI469781B (zh) | 黏結劑於製造貯存安定性調合物上之用途 | |
| KR20160104709A (ko) | 난수용성 화합물용 약제학적 조성물 | |
| JP2023509629A5 (https=) | ||
| NO340156B1 (no) | Fremgangsmåte for fremstilling av en fast, oralt administrerbar farmasøytisk sammensetning | |
| TW201929839A (zh) | 一種控釋藥物組合物及其製備方法 | |
| JP2023540137A5 (https=) | ||
| JP2007528901A5 (https=) | ||
| JP2011503048A5 (https=) | ||
| JP2009215293A (ja) | 食物なしでジプラシドンを投与するための方法、剤形、およびキット | |
| JP2019501216A5 (https=) | ||
| TW201200165A (en) | Oral solid extended release dosage form | |
| HU204194B (en) | Process for producing instant and retard gemfibrosil compositions | |
| JP6904955B2 (ja) | アプレミラスト徐放性製剤 | |
| CN102548543B (zh) | 具有改进的溶出率和最小的副作用的缓释的西洛他唑片剂 | |
| JP2010521437A5 (https=) | ||
| CN107072954B (zh) | 用于口服给药的包含洛贝格列酮的药物组合物 | |
| WO2016012898A1 (en) | Oral pharmaceutical composition of lurasidone | |
| JP2007510654A (ja) | 分極した酸素原子を有するポリマーを含むマトリクスからの正に荷電した薬理学的活性分子の徐放 | |
| CN112533608B (zh) | 包含1,3,5-三嗪衍生物或其盐的固体药物组合物 | |
| JP2019034914A (ja) | 良好な徐放性を有する、レボドパ含有小型化錠剤 | |
| CA2854612C (en) | Delivery systems for improving oral bioavailability of fenobam, its hydrates, and salts | |
| EP4398910A1 (en) | A capsule formulation comprising macitentan | |
| WO2023038600A1 (en) | A capsule formulation comprising macitentan |